A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer

By Yardley Denise   Burris Howard   Peacock Nancy   Raefsky Eric   Melnik Marianne   Inhorn Roger   Shipley Dianna   Hainsworth John  

Breast Cancer Research and Treatment, Vol. 123, Iss. 2, 2010-09 ,pp. : 471-475

Springer Publishing Company

Access to resources Recommend Favorite

Effect of HER2 status on distant recurrence in early stage breast cancer

By Hess Kenneth  

Breast Cancer Research and Treatment, Vol. 137, Iss. 2, 2013-01 ,pp. : 449-455

Springer Publishing Company

Access to resources Recommend Favorite

Prevalence of germline TP53 mutations in HER2+ breast cancer patients

By Rath Michelle  

Breast Cancer Research and Treatment, Vol. 139, Iss. 1, 2013-05 ,pp. : 193-198

Springer Publishing Company

Access to resources Recommend Favorite

Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients

By Bighin Claudia   Pronzato Paolo   Del Mastro Lucia  

Future Oncology, Vol. 9, Iss. 7, 2013-07 ,pp. : 955-957

Future Medicine

Access to resources Recommend Favorite

A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer

By Somlo G.   Martel C.   Lau S.   Frankel P.   Ruel C.   Gu L.   Hurria A.   Chung C.   Luu T.   Morgan R.   Leong L.   Koczywas M.   McNamara M.   Russell C.   Kane S.  

Breast Cancer Research and Treatment, Vol. 131, Iss. 3, 2012-02 ,pp. : 899-906

Springer Publishing Company

Access to resources Recommend Favorite